Mild cognitive impairment (MCI) has been considered as a pre-dementia stage, although the factors leading to Alzheimer’s disease (AD) conversion remain controversial.
Objective:
Evaluate whether TOMM40 poly-T (TOMM40′ 523) polymorphism is associated with the risk and conversion time from MCI to AD and secondly with AD cerebrospinal fluid (CSF) biomarkers, disentangling the APOE genotype.
Methods:
147 AD patients, 102 MCI patients, and 105 cognitively normal controls were genotyped for poly-T polymorphism. MCI patients were subdivided into two groups, the group of patients that converted to AD (MCI-AD) and the group of those that remained stable (MCI-S).
Results:
TOMM40′ 523 L allele was significantly more frequent in the MCI-AD group and having at least one L allele significantly increased the risk of conversion from MCI to AD (OR = 8.346, p < 0.001, 95% CI: 2.830 to 24.617). However, when adjusted for the presence of APOEɛ4 allele, both the L allele and ɛ4 allele lost significance in the model (p > 0.05). We then analyzed the APOEɛ4-TOMM40′ 523 L haplotype and observed that patients carrying this haplotype had significantly higher risk (OR = 5.83; 95% CI = 2.30–14.83) and mean lower times of conversion to AD (p = 0.003). This haplotype was also significantly associated with a biomarker profile compatible with AD (p = 0.007).
Conclusion:
This study shows that the APOEɛ4-TOMM40′ 523 L haplotype is associated with a higher risk and shorter times of conversion from MCI to AD, possibly driven by CSF biomarkers and mitochondrial dysfunction.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
4.
CummingsJ, LeeG, MortsdorfT, RitterA, ZhongK (2017) Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (N Y)3, 367–384.
5.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
6.
SaundersAM, StrittmatterWJ, SchmechelD, St. George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, HuletteC, CrainB, GoldgaberD, RosesAD (1993) Association of apolipoprotein E allele ɛ4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
7.
Elias-SonnenscheinLS, ViechtbauerW, RamakersIHGB, VerheyFRJ, VisserPJ (2011) Predictive value of APOE ɛ4 allele for progression from MCI to AD-type dementia: A meta-analysis. J Neurol Neurosurg Psychiatry82, 1149–1156.
8.
LiJ-Q, TanL, WangH-F, TanM-S, TanL, XuW, ZhaoQ-F, WangJ, JiangT, YuJ-T (2016) Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: A systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry87, 476–484.
9.
DukartJ, SambataroF, BertolinoA (2016) Accurate prediction of conversion to Alzheimer’s disease using imaging, genetic, and neuropsychological biomarkers. J Alzheimers Dis49, 1143–1159.
10.
LópezME, TurreroA, CuestaP, López-SanzD, BruñaR, MarcosA, GilP, YusM, BarabashA, CabranesJA, MaestúF, FernándezA (2016) Searching for primary predictors of conversion from mild cognitive impairment to Alzheimer’s disease: A multivariate follow-up study. J Alzheimers Dis52, 133–143.
11.
GuptaY, LamaRK, KwonG-R (2019) Prediction and classification of Alzheimer’s disease based on combined features from apolipoprotein-E genotype, cerebrospinal fluid, MRI, and FDG-PET imaging biomarkers. Front Comput Neurosci13, 1–18.
12.
MartinER, LaiEH, GilbertJR, RogalaAR, AfshariAJ, RileyJ, FinchKL, StevensJF, LivakKJ, SlotterbeckBD, SliferSH, WarrenLL, ConneallyPM, SchmechelDE, PurvisI, Pericak-VanceMA, RosesAD, VanceJM (2000) SNPing away at complex diseases: Analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet67, 383–394.
13.
YuC-E, SeltmanH, PeskindER, GallowayN, ZhouPX, RosenthalE, WijsmanEM, TsuangDW, DevlinB, SchellenbergGD (2007) Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer’s disease: Patterns of linkage disequilibrium and disease/marker association. Genomics89, 655–665.
RosesAD, LutzMW, Amrine-MadsenH, SaundersAM, CrenshawDG, SundsethSS, HuentelmanMJ, Welsh-BohmerKA, ReimanEM (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacogenomics J10, 375–384.
16.
LutzMW, CrenshawDG, SaundersAM, RosesAD (2010) Genetic variation at a single locus and age of onset for Alzheimer’s disease. Alzheimers Dement6, 125–131.
17.
ProkopenkoI, MiyakawaG, ZhengB, HeikkinenJ, QuayleD, Udeh-MomohC, ClaringbouldA, NeumannJ, HayturalH, KaakinenM, LoizidouE, MeissnerE, BertramL, GvericD, GentlemanS, AttemsJ, PerneczkyR, ArzbergerT, MugliaP, MiddletonL (2019) Alzheimer’s disease pathology explains association between dementia with Lewy bodies and APOE-ɛ4/TOMM40 long poly-T repeat allele variants. Alzheimers Dement (N Y)5, 814–824.
18.
JunG, VardarajanBN, BurosJ, YuC-E, HawkMV, DombroskiBA, CranePK, LarsonEB, MayeuxR, HainesJL, LunettaKL, Pericak-VanceMA, SchellenbergGD, FarrerLA (2012) Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol69, 1270–1279.
19.
LiG, BekrisLM, LeongL, SteinbartEJ, ShoferJB, CranePK, LarsonEB, PeskindER, BirdTD, YuC-E (2013) TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in individuals with APOE ɛ3/ɛ3. Alzheimers Dement9, 554–561.
20.
HelisalmiS, HallA, MeriläinenEH, VäisänenV, KoivistoAM, HerukkaSK, LaitinenM, SoininenH, HiltunenM (2014) The effect of TOMM40 poly-T repeat lengths on age of onset and cerebrospinal fluid biomarkers in Finnish Alzheimer’s disease patients. Neurodegener Dis14, 204–208.
21.
Chiba-FalekO, GottschalkWK, LutzMW (2018) The effects of the TOMM40 poly-T alleles on Alzheimer’s disease phenotypes. Alzheimers Dement14, 692–698.
22.
CrenshawDG, GottschalkWK, LutzMW, GrossmanI, SaundersAM, BurkeJR, Welsh-BohmerKA, BrannanSK, BurnsDK, RosesAD (2013) Using genetics to enable studies on the prevention of Alzheimer’s disease. Clin Pharmacol Therap93, 177–185.
23.
LutzMW, SundsethSS, BurnsDK, SaundersAM, HaydenKM, BurkeJR, Welsh-BohmerKA, RosesAD (2016) A genetics-based biomarker risk algorithm for predicting risk of Alzheimer’s disease. Alzheimers Dement (N Y)2, 30–44.
LehallierB, EssiouxL, GayanJ, AlexandridisR, NikolchevaT, Wyss-CorayT, BritschgiM (2016) Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease. JAMA Neurology73, 203–212.
26.
LaczóJ, AndelR, VyhnalekM, MatoskaV, KaplanV, NedelskaZ, LerchO, GazovaI, MoffatSD, HortJ (2015) The effect of TOMM40 on spatial navigation in amnestic mild cognitive impairment. Neurobiol Aging36, 2024–2033.
27.
BaldeirasI, SantanaI, ProençaMT, GarruchoMH, PascoalR, RodriguesA, DuroD, OliveiraCR (2010) Oxidative damage and progression to Alzheimer’s disease in patients with mild cognitive impairment. J Alzheimers Dis21, 1165–1177.
28.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
29.
GuerreiroM, SilvaAP, BotelhoMA (2003) Avaliacão Breve do Estado Mental: Escalas e Testes na Demência, Grupo de estudos de Envelhecimento Cerebral e Demencia, pp. 27-32.
30.
NasreddineZS, PhillipsNA, BédirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
31.
FreitasS, SimõesMR, AlvesL, SantanaI (2011) Montreal Cognitive Assessment (MoCA): Normative study for the Portuguese population. J Clin Exp Neuropsychol33, 989–996.
32.
MohsRC, RosenWG, DavisKL (1983) The Alzheimer’s disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull19, 448–450.
33.
Rosen WgMRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
34.
GuerreiroM, FonsecaS, BarretoJ (2003) Avaliacão Breve do Estado Mental: Escalas e Testes na Demência, Grupo de estudos de Envelhecimento Cerebral e Demencia, pp. 33-49.
35.
GuerreiroM (1998) Contribution of neuropsychology to the study of dementias. Ph.D. thesis, Faculty of Medicine of Lisbon, Lisbon, Portugal.
GélinasI, GauthierL, McIntyreM, GauthierS (1999) Development of a functional measure for persons with Alzheimer’s disease: The disability assessment for dementia. Am J Occup Ther53, 471–481.
38.
LeitãoO (2008) Avaliação Breve do Estado Mental: Escalas e Testes na Demência, Grupo de estudos de Envelhecimento Cerebral e Demencia, pp. 107-110.
39.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology48, 10–16.
40.
LeitãoO, NinaA (2003) Avaliacão Breve do Estado Mental: Escalas e Testes na Demência, Grupo de estudos de Envelhecimento Cerebral e Demencia, pp. 67-86.
41.
PetersenRC, StevensJC, GanguliM, TangalosEG, CummingsJL, DeKoskyST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1133–1142.
42.
RománGC, TatemichiTK, ErkinjunttiT, CummingsJL, MasdeuJC, GarciaJH, AmaducciL, OrgogozoJ-M, BrunA, HofmanA, MoodyDM, O’BrienMD, YamaguchiT, GrafmanJ, DrayerBP, BennettDA, FisherM, OgataJ, KokmenE, BermejoF, WolfPA, GorelickPB, BickKL, PajeauAK, BellMA, DeCarliC, CulebrasA, KorczynAD, BogousslavskyJ, HartmannA, ScheinbergP (1993) Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology43, 250–250.
43.
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., text rev).
44.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–939.
45.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
46.
OliveiraCR, RosaMS, PintoAM, BotelhoA, MoraisA, VeríssimoMT (2010) Estudo do Perfil do Envelhecimento da População Portuguesa.
LinnertzC, SaundersAM, LutzMW, CrenshawDM, GrossmanI, BurnsDK, WhitfieldKE, HauserMA, McCarthyJJ, UlmerM, AllinghamR, Welsh-BohmerKA, RosesAD, Chiba-FalekO (2012) Characterization of the Poly-T variant in the TOMM40 gene in diverse populations. PLoS One7, e30994.
49.
ChuSH, RoederK, FerrellRE, DevlinB, DeMichele-SweetMAA, KambohMI, LopezOL, SweetRA (2011) TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiol Aging32, 2328.e2321–2328.e2329.
50.
del CampoM, MollenhauerB, BertolottoA, EngelborghsS, HampelH, SimonsenAH, KapakiE, KruseN, BastardNL, LehmannS, MolinuevoJL, ParnettiL, Perret-LiaudetA, Sáez-ValeroJ, SakaE, UrbaniA, VanmechelenE, VerbeekM, VisserPJ, TeunissenC (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. Biomark Med6, 419–430.
51.
BaldeirasI, SantanaI, LeitãoMJ, RibeiroMH, PascoalR, DuroD, LemosR, SantiagoB, AlmeidaMR, OliveiraCR (2015) Cerebrospinal fluid Aβ40 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Sci358, 308–316.
HulstaertF, BlennowK, IvanoiuA, SchoonderwaldtHC, RiemenschneiderM, DeynPPD, BancherC, CrasP, WiltfangJ, MehtaPD, IqbalK, PottelH, VanmechelenE, VandersticheleH (1999) Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology52, 1555–1562.
54.
MaruszakA, PepłońskaB, SafranowK, Chodakowska-ŻebrowskaM, BarcikowskaM, ŻekanowskiC (2012) TOMM40 rs10524523 polymorphism’s role in late-onset Alzheimer’s disease and in longevity. J Alzheimers Dis28, 309–322.
55.
Monge-ArgilésJA, Gasparini-BerenguerR, Gutierrez-AgullóM, Muñoz-RuizC, Sánchez-PayáJ, Leiva-SantanaC (2016) Influence of APOE genotype on Alzheimer’s disease CSF biomarkers in a Spanish population. Biomed Res Int2016, 1390620.
56.
LeoniV (2011) The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. Clin Chem Lab Med49, 375–383.
57.
ToledoJB, ZetterbergH, van HartenAC, GlodzikL, Martinez-LageP, Bocchio-ChiavettoL, RamiL, HanssonO, SperlingR, EngelborghsS, OsorioRS, VandersticheleH, VandijckM, HampelH, TeiplS, MoghekarA, AlbertM, HuWT, Monge ArgilésJA, GorostidiA, TeunissenCE, De DeynPP, HymanBT, MolinuevoJL, FrisoniGB, LinazasoroG, de LeonMJ, van der FlierWM, ScheltensP, BlennowK, ShawLM, TrojanowskiJQ, on behalf of the Alzheimer’s Disease Neuroimaging Initiative (2015) Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain138, 2701–2715.
58.
CruchagaC, NowotnyP, KauweJSK, RidgePG, MayoK, BertelsenS, HinrichsA, FaganAM, HoltzmanDM, MorrisJC, GoateAM, Alzheimer’s Disease Neuroimaging Initiative (2011) Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol68, 1013–1019.
59.
PomaraN, BrunoD, NierenbergJJ, SidtisJJ, MartiniukFT, MehtaPD, ZetterbergH, BlennowK (2011) TOMM40 poly-T variants and cerebrospinal fluid amyloid beta levels in the elderly. Neurochem Res36, 1124–1128.
60.
RosesAD, LutzMW, SaundersAM, GoldgaberD, SaulR, SundsethSS, AkkariPA, RosesSM, GottschalkWK, WhitfieldKE, VostrovAA, HauserMA, AllinghamRR, BurnsDK, Chiba-FalekO, Welsh-BohmerKA (2014) African-American TOMM40’523-APOE haplotypes are admixture of West African and Caucasian alleles. Alzheimers Dement10, 592–601.e592.
61.
NishimuraA, NonomuraH, TanakaS, YoshidaM, MaruyamaY, AritomiY, SaundersAM, BurnsDK, LutzMW, RunyanG, LaiE, BudurK, RosesAD (2017) Characterization of APOE and TOMM40 allele frequencies in the Japanese population. Alzheimers Dement (N Y)3, 524–530.
62.
YuL, LutzMW, WilsonRS, BurnsDK, RosesAD, SaundersAM, YangJ, GaiteriC, De JagerPL, BarnesLL, BennettDA (2017) APOE ɛ4-TOMM40 ‘523 haplotypes and the risk of Alzheimer’s disease in older Caucasian and African Americans. PLoS One12, e0180356.
63.
KanekiyoT, XuH, BuG (2014) ApoE and Aβ in Alzheimer’s disease: Accidental encounters or partners?Neuron81, 740–754.
64.
LiuC-C, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
65.
HumphriesAD, StreimannIC, StojanovskiD, JohnstonAJ, YanoM, HoogenraadNJ, RyanMT (2005) Dissection of the mitochondrial import and assembly pathway for human Tom40. J Biol Chem280, 11535–11543.
66.
PfannerN, WarscheidB, WiedemannN (2019) Mitochondrial proteins: From biogenesis to functional networks. Nat Rev Mol Cell Biol20, 267–284.
67.
AnandatheerthavaradaHK, BiswasG, RobinM-A, AvadhaniNG (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol161, 41–54.
68.
Hansson PetersenCA, AlikhaniN, BehbahaniH, WiehagerB, PavlovPF, AlafuzoffI, LeinonenV, ItoA, WinbladB, GlaserE, AnkarcronaM (2008) The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A105, 13145–13150.
69.
WoodH (2020) Mitochondrial dysfunction manifests in the early stages of Alzheimer disease. Nat Rev Neurol16, 242–242.
Mahoney-SanchezL, BelaidiAA, BushAI, AytonS (2016) The complex role of apolipoprotein E in Alzheimer’s disease: An overview and update. J Mol Neurosci60, 325–335.
72.
HarrisFM, BrechtWJ, XuQ, TesseurI, KekoniusL, Wyss-CorayT, FishJD, MasliahE, HopkinsPC, Scearce-LevieK, WeisgraberKH, MuckeL, MahleyRW, HuangY (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A100, 10966–10971.
73.
ChangS, MaTr, MirandaRD, BalestraME, MahleyRW, HuangY (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A102, 18694–18699.
74.
NakamuraT, WatanabeA, FujinoT, HosonoT, MichikawaM (2009) Apolipoprotein E4 (1–272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener4, 35.
75.
GottschalkWK, LutzMW, HeYT, SaundersAM, BurnsDK, RosesAD, Chiba-FalekO (2014) The broad impact of TOM40 on neurodegenerative diseases in aging. J Parkinsons Dis Alzheimers Dis1, 1–25.
76.
HedskogL, BrohedeJ, WiehagerB, PinhoCM, RevathikumarP, LiliusL, GlaserE, GraffC, KarlströmH, AnkarcronaM (2012) Biochemical studies of poly-T variants in the Alzheimer’s disease associated TOMM40 gene. J Alzheimers Dis31, 527–536.
77.
ZeitlowK, CharlambousL, NgI, GagraniS, MihovilovicM, LuoS, RockDL, SaundersA, RosesAD, GottschalkWK (2017) The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer’s disease. Biochim Biophys Acta1863, 2973–2986.
